Market Cap 17.22M
Revenue (ttm) 27.47M
Net Income (ttm) -26.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -96.83%
Debt to Equity Ratio 0.00
Volume 75,983,906
Avg Vol 2,871,572
Day's Range N/A - N/A
Shares Out 97.28M
Stochastic %K 22%
Beta 1.57
Analysts Strong Sell
Price Target $3.33

Company Profile

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 949 2680
Address:
40 Guest Street, Boston, United States
Gainermaxim
Gainermaxim Apr. 8 at 9:39 AM
$CUE Need some volume and this gonna rockkkkkk
0 · Reply
Tanner_charting
Tanner_charting Apr. 8 at 9:25 AM
0 · Reply
Bio_Be_Dirty
Bio_Be_Dirty Apr. 8 at 5:46 AM
$CUE dead , get the coffin
0 · Reply
Ph777trader
Ph777trader Apr. 8 at 3:27 AM
0 · Reply
TraderJoeee
TraderJoeee Apr. 8 at 3:05 AM
$CUE and we are back to $0.20 in overnight
1 · Reply
_SupermanTrdez
_SupermanTrdez Apr. 8 at 1:36 AM
Keep a close watch on CYCU ✅ News this morning and plus got a $7 dollar buy rating! -Cybersecurity is becoming mandatory infrastructure and CYCU is right in the middle of it. -While the world is dealing with rising cyber threats, this company is building backlog and contracts. Add in short pressure and you’ve got serious squeeze potential if volume steps in. With markets heating up CYCU can be a big runner! $CETX $LNAI $CUE $PLUG //.12
1 · Reply
GordoHLYK13
GordoHLYK13 Apr. 8 at 1:19 AM
$CUE today’s R&D Day presentation highlights a significant shift in momentum. Management shared compelling new data on CUE-401, confirming its potential as a "master switch" for treating autoimmune diseases by restoring immune balance. Beyond the science, the outlook is bolstered by tangible progress: • $7.5M Milestone: Just last week, Boehringer Ingelheim triggered a $7.5 million payment after selecting the first compound for lead optimization in their B cell depletion partnership. • Clinical Path: The company is fully focused on moving CUE-401 into clinical trials by the second half of this year. • Leadership Transition: With Lucinda Warren stepping in as Interim CEO, the focus has pivoted to executing creative deals and reclaiming rights to key assets like CUE-401 to drive shareholder value. The stock has been under pressure, but the pipeline development and recent non-dilutive cash injection provide a much-needed positive catalyst.
0 · Reply
GordoHLYK13
GordoHLYK13 Apr. 7 at 11:37 PM
$CUE CUE-401 is actually high-level science — not fluff. It’s a first-in-class approach combining IL-2 + TGF-β to act like a “master switch,” turning inflammatory T-cells into regulatory T-cells and restoring immune balance — something most autoimmune drugs don’t do (they just suppress symptoms).  Today’s presentation basically reinforced 3 key points: • Strong preclinical safety (no major adverse events) • Selective Treg expansion (precision vs broad immunosuppression) • Clear path toward IND / human trials  Why Warren matters: Lucinda Warren is a capital allocator + dealmaker, not just a scientist — exactly what a small biotech needs right now. Translation: 👉 More partnerships 👉 More non-dilutive cash (like the $7.5M) 👉 Sharper execution vs prior leadership Bottom line: CUE-401 = high-upside, differentiated mechanism Warren = execution + funding focus That combo is what turns science into shareholder value.
1 · Reply
focafoca99
focafoca99 Apr. 7 at 9:30 PM
$CUE says Boehringer Ingelheim selected the first compound for lead optimization under their collaboration, triggering a $7.5 million milestone expected in May.
0 · Reply
NEWYORKSILVERKING
NEWYORKSILVERKING Apr. 7 at 8:46 PM
$CUE When you`re a micro cap biotech and get awarded a milestone payment that`s nearly half the market cap why wouldn`t you put out an actual press release after filing the 8k with the SEC?
0 · Reply
Latest News on CUE
Cue Biopharma Announces CEO Transition

Mar 27, 2026, 4:05 PM EDT - 11 days ago

Cue Biopharma Announces CEO Transition


Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026

Mar 26, 2026, 8:00 AM EDT - 12 days ago

Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026


Cue Biopharma Announces Pricing of $10 Million Public Offering

Dec 19, 2025, 8:00 AM EST - 3 months ago

Cue Biopharma Announces Pricing of $10 Million Public Offering


Cue Biopharma Announces Proposed Public Offering

Dec 18, 2025, 4:02 PM EST - 3 months ago

Cue Biopharma Announces Proposed Public Offering


Cue Biopharma to Host Virtual Investor Event on May 15, 2025

May 8, 2025, 8:00 AM EDT - 11 months ago

Cue Biopharma to Host Virtual Investor Event on May 15, 2025


Cue Biopharma to Host Business Update Call and Webcast

Apr 14, 2025, 5:02 PM EDT - 1 year ago

Cue Biopharma to Host Business Update Call and Webcast


Cue Biopharma Announces Strategic Organizational Transition

Nov 14, 2024, 8:00 AM EST - 1 year ago

Cue Biopharma Announces Strategic Organizational Transition


Cue Biopharma Announces Proposed Public Offering

Sep 26, 2024, 11:10 PM EDT - 1 year ago

Cue Biopharma Announces Proposed Public Offering


Cue Biopharma to Host Investor Call

Jun 7, 2023, 8:00 AM EDT - 3 years ago

Cue Biopharma to Host Investor Call


Gainermaxim
Gainermaxim Apr. 8 at 9:39 AM
$CUE Need some volume and this gonna rockkkkkk
0 · Reply
Tanner_charting
Tanner_charting Apr. 8 at 9:25 AM
0 · Reply
Bio_Be_Dirty
Bio_Be_Dirty Apr. 8 at 5:46 AM
$CUE dead , get the coffin
0 · Reply
Ph777trader
Ph777trader Apr. 8 at 3:27 AM
0 · Reply
TraderJoeee
TraderJoeee Apr. 8 at 3:05 AM
$CUE and we are back to $0.20 in overnight
1 · Reply
_SupermanTrdez
_SupermanTrdez Apr. 8 at 1:36 AM
Keep a close watch on CYCU ✅ News this morning and plus got a $7 dollar buy rating! -Cybersecurity is becoming mandatory infrastructure and CYCU is right in the middle of it. -While the world is dealing with rising cyber threats, this company is building backlog and contracts. Add in short pressure and you’ve got serious squeeze potential if volume steps in. With markets heating up CYCU can be a big runner! $CETX $LNAI $CUE $PLUG //.12
1 · Reply
GordoHLYK13
GordoHLYK13 Apr. 8 at 1:19 AM
$CUE today’s R&D Day presentation highlights a significant shift in momentum. Management shared compelling new data on CUE-401, confirming its potential as a "master switch" for treating autoimmune diseases by restoring immune balance. Beyond the science, the outlook is bolstered by tangible progress: • $7.5M Milestone: Just last week, Boehringer Ingelheim triggered a $7.5 million payment after selecting the first compound for lead optimization in their B cell depletion partnership. • Clinical Path: The company is fully focused on moving CUE-401 into clinical trials by the second half of this year. • Leadership Transition: With Lucinda Warren stepping in as Interim CEO, the focus has pivoted to executing creative deals and reclaiming rights to key assets like CUE-401 to drive shareholder value. The stock has been under pressure, but the pipeline development and recent non-dilutive cash injection provide a much-needed positive catalyst.
0 · Reply
GordoHLYK13
GordoHLYK13 Apr. 7 at 11:37 PM
$CUE CUE-401 is actually high-level science — not fluff. It’s a first-in-class approach combining IL-2 + TGF-β to act like a “master switch,” turning inflammatory T-cells into regulatory T-cells and restoring immune balance — something most autoimmune drugs don’t do (they just suppress symptoms).  Today’s presentation basically reinforced 3 key points: • Strong preclinical safety (no major adverse events) • Selective Treg expansion (precision vs broad immunosuppression) • Clear path toward IND / human trials  Why Warren matters: Lucinda Warren is a capital allocator + dealmaker, not just a scientist — exactly what a small biotech needs right now. Translation: 👉 More partnerships 👉 More non-dilutive cash (like the $7.5M) 👉 Sharper execution vs prior leadership Bottom line: CUE-401 = high-upside, differentiated mechanism Warren = execution + funding focus That combo is what turns science into shareholder value.
1 · Reply
focafoca99
focafoca99 Apr. 7 at 9:30 PM
$CUE says Boehringer Ingelheim selected the first compound for lead optimization under their collaboration, triggering a $7.5 million milestone expected in May.
0 · Reply
NEWYORKSILVERKING
NEWYORKSILVERKING Apr. 7 at 8:46 PM
$CUE When you`re a micro cap biotech and get awarded a milestone payment that`s nearly half the market cap why wouldn`t you put out an actual press release after filing the 8k with the SEC?
0 · Reply
lambo2220
lambo2220 Apr. 7 at 7:54 PM
0 · Reply
SirDuncan
SirDuncan Apr. 7 at 7:16 PM
$CUE after taking a closer look at the tape action, it is abundantly clear that a large seller used this as an opportunity to unload a massive position. Looks like they wanted out just prior to the reverse split later this month.
1 · Reply
Legends0fWick
Legends0fWick Apr. 7 at 6:49 PM
Small cap is hot, Massive breakout starting on CYCU 🚨 CYCU with massive cyber security news today. With just 2M float can CYCU be the next parabolic runner? Make sure you have ticker CYCU on watch. Market is looking super hot right now, CYCU can go big!! $MIGI $CUE $IPST $ARTL ..//11
0 · Reply
suavetrader945
suavetrader945 Apr. 7 at 6:38 PM
$CUE What’s the move with this one
0 · Reply
DayTrade_4Life
DayTrade_4Life Apr. 7 at 5:54 PM
🔥FINAL TALLY FROM THE WL & ALERTS TODAY. That's enough money for now. 🤔Ready to make that change to Profitability and Learning a Simple Strategy to take you there. Then come Join Us. See Profile. AIXI: $1 to 2.71 (171%) HCAI: .23 to .54 (134%) IPST: .34 to .61 (79%) RDGT: .03 to .05 (66%) CETX: 1.30 to 1.89 (45%) $SILO: .50 to .72 (44%) $HUBC: .10 to .14 (40%) $TDIC: .23 to .29 (26%) $CUE: .25 to .29 (16%) $AGPU: 5.26 to $6 (14%) SKYQ: 6.50 to 7.34 (12%) LNAI: .45 to .50 (11%)
1 · Reply
GordoHLYK13
GordoHLYK13 Apr. 7 at 5:48 PM
$CUE $JNJ you can spin it however you want, but facts don’t lie — Cue just secured a $7.5M milestone payment from Boehringer Ingelheim, proving real partnership traction and ongoing value creation. Today’s R&D presentation wasn’t hype — it reinforced progress on CUE-401, a next-gen platform in a massive unmet market, now under new interim CEO leadership focused on execution from $JNJ . Call it what you want… but partnerships, funding, and pipeline progress don’t scream “failure” — they scream momentum. 🚀
0 · Reply
Gainermaxim
Gainermaxim Apr. 7 at 5:41 PM
$CUE I'm in let's see!!!
0 · Reply
lambo2220
lambo2220 Apr. 7 at 5:37 PM
0 · Reply
Tamiru
Tamiru Apr. 7 at 5:01 PM
$AIXI down 📉👇 all u should come $CUE 👀👀 📈
0 · Reply
GordoHLYK13
GordoHLYK13 Apr. 7 at 4:51 PM
$CUE CUE-401: The Quick Reality Check The Science (Bullish) * Nobel-Grade Asset: CUE-401 is a "master switch" for autoimmune diseases. • The Experts: Top doctors confirmed it’s safe and ready for human trials. • The Cash: Just secured a $7.5M milestone from Boehringer Ingelheim. • The Goal: IND filing in Q2 2026 (this quarter). The Stock (Bearish) * Price Trap: Spiked to $0.25 today but dumped back to $0.18. • Massive Volume: 61M+ shares traded; it's a violent tug-of-war. • The Bottleneck: The market is ignoring the science until the April 13th meeting clears the air. IND Progress: Any PR confirming the specific filing date. Bottom Line: The medicine is elite, but the stock is currently fighting until the financial restructuring is finished.
1 · Reply
GordoHLYK13
GordoHLYK13 Apr. 7 at 4:34 PM
$CUE You keep calling it “failure” like that’s the whole story. 101 didn’t hit, sure—but that’s not the end of the pipeline. Big difference between one miss and the whole thesis collapsing. You’re acting like it’s over when it’s clearly still evolving.
0 · Reply
GordoHLYK13
GordoHLYK13 Apr. 7 at 4:32 PM
$CUE Nah, you off on that one. You said “reverse split in two weeks” like it’s a done deal—nothing confirmed there. Let me be clear: price runs first. If anything, this moves toward $1 before any talk of a split. The setup doesn’t scream desperation—it’s positioning. You can talk facts, but don’t twist the narrative. I’ll stick with the chart and the story, not assumptions.
1 · Reply